North America Micro Invasive Glaucoma Surgery (MIGS) Devices Market, By Product (MIGS Stents, MIGS Shunts, Others), Target (Trabecular Meshwork, Suprachoroidal Space, Subconjunctival Filtration, Reducing Aqueous Production), Surgery Type (Glaucoma in Conjunction with Cataract, Stand-Alone Glaucoma), End User (Hospital Outpatient Departments (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), Others), Distribution Channel (Direct Tender, Retail Sales) - Industry Trends and Forecast to 2030.
North America Micro Invasive Glaucoma Surgery (MIGS) Devices Market Analysis and Size
The field of ophthalmology has seen significant technological advancements in recent years, leading to the development of safer and more effective MIGS devices. These devices are less invasive, have shorter recovery times, and offer better outcomes, making them more appealing to both patients and healthcare providers. Public awareness of glaucoma and its potential consequences is growing, which encourages early diagnosis and treatment. Patients are increasingly seeking options that not only control intraocular pressure but also have a lower risk of complications compared to traditional glaucoma surgeries.
Data Bridge Market Research analyzes that the North America micro invasive glaucoma surgery (MIGS) devices market which was USD 191.70 million in 2022, would rocket up to USD 5,589.67 million by 2030, and is expected to undergo a CAGR of 34.4% during the forecast period. “MIGS Stents” dominates the product segment of the North America micro invasive glaucoma surgery (MIGS) devices market owing to the increasing investment in healthcare. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (MIGS Stents, MIGS Shunts and Others), Target (Trabecular Meshwork, Suprachoroidal Space, Subconjunctival Filtration, Reducing Aqueous Production), Surgery Type (Glaucoma in Conjunction with Cataract, Stand-Alone Glaucoma), End User (Hospital Outpatient Departments (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS), Others), Distribution Channel (Direct Tender, Retail Sales)
|
|
Countries Covered
|
U.S., Canada, Mexico
|
|
Market Players Covered
|
AbbVie (U.S.), BVI (U.S.), Ellex (Australia), Glaukos Corporation (U.S.), Johnson and Johnson (U.S.), Alcon (Switzerland), Microsurgical technology (U.S.), New World Medical (U.S.), Santen Pharmaceutical (Japan), Nova Eye Medical Limited (Australia), Belkin Vision (U.S.), Sight Scientific (U.S.)
|
|
Market Opportunities
|
|
Market Definition
The micro invasive glaucoma surgery (MIGS) devices market can be defined as the segment of the medical device industry that focuses on the development, manufacturing, and distribution of minimally invasive surgical devices and technologies used in the treatment of glaucoma. Glaucoma is a group of eye conditions that can lead to progressive damage to the optic nerve, often caused by elevated intraocular pressure (IOP). MIGS devices are designed to reduce IOP and manage glaucoma through less invasive procedures compared to traditional glaucoma surgeries.
North America Micro Invasive Glaucoma Surgery (MIGS) Devices Market Dynamics
Drivers
- Rising technological advancements
Advances in ophthalmic technology have led to the development of more effective and less invasive MIGS devices. These innovations are attractive to both patients and healthcare providers, as they reduce the risk of complications, improve patient outcomes, and offer quicker recovery times.
- Growing aging population
The aging demographic in North America is a significant driver for the MIGS devices market. Glaucoma is more common among older individuals, and as the population ages, the prevalence of glaucoma cases increases. This demographic shift has led to a greater demand for innovative and less invasive glaucoma treatment options like MIGS devices to cater to the needs of the aging population.
Opportunity
- Increasing awareness for the prevention of blindness
Greater public awareness of glaucoma and its potential consequences has encouraged early diagnosis and treatment. Patients are increasingly seeking options that not only control intraocular pressure but also have a lower risk of complications compared to traditional glaucoma surgeries.
Restraint/Challenge
- Reimbursement Challenges
While reimbursement policies can be a driver, they can also be a restraint. Inconsistent reimbursement policies or limited coverage for MIGS procedures can hinder patient access and the willingness of healthcare providers to offer these treatments.
This North America micro invasive glaucoma surgery (MIGS) devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the micro invasive glaucoma surgery (MIGS) devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In January 2022, Glaukos announced GLK=301's first patient enrolment in the Phase II clinical trial for dry eye disease. After the successful approval from the regulatory body, this drug will help the company grow its business segment
- In January 2022, Alcon acquired Ivantis, developer of the novel Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This surgical device is designed to lower eye pressure for open-angle glaucoma patients. This acquisition will enhance the company’s portfolio in eye surgery segment
North America Micro Invasive Glaucoma Surgery (MIGS) Devices Market Scope
The micro invasive glaucoma surgery (MIGS) devices market is segmented on the basis of product, target, surgery, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- MIGS Stents
- MIGS Shunts
- Others
Target
- Trabecular Meshwork
- Suprachoroidal Space
- Subconjunctival Filtration
- Reducing Aqueous Production
Surgery
- Glaucoma in Conjunction With Cataract
- Stand-Alone Glaucoma
End User
- Hospital Outpatient Departments (HOPD)
- Ophthalmology Clinics
- Ambulatory Surgery Centers (ASCS)
- Others
Distribution Channel
- Direct Tender
- Retail Sales
North America Micro Invasive Glaucoma Surgery (MIGS) Devices Market Regional Analysis/Insights
North America micro invasive glaucoma surgery (MIGS) devices market is analyzed, and market size insights and trends are provided by country, product, target, surgery, end user, and distribution channel as referenced above.
The countries covered in the North America Micro Invasive Glaucoma Surgery (MIGS) devices market report are U.S., Canada and Mexico.
The U.S. is expected to dominate the micro invasive glaucoma surgery (MIGS) devices market due to the higher level of investments by various manufacturers and increasing demand for capnography consumables in the region. The U.S. is also expected to be the fastest growing country in the market in the forecast period.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The micro invasive glaucoma surgery (MIGS) devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for micro invasive glaucoma surgery (MIGS) devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the micro invasive glaucoma surgery (MIGS) devices market. The data is available for historic period 2010-2020.
Competitive Landscape and Micro Invasive Glaucoma Surgery (MIGS) Devices Market Share Analysis
The micro invasive glaucoma surgery (MIGS) devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to micro invasive glaucoma surgery (MIGS) devices market.
Some of the major players operating in the micro invasive glaucoma surgery (MIGS) devices market are:
- AbbVie (U.S.)
- BVI (U.S.)
- Ellex (Australia)
- Glaukos Corporation (U.S.)
- Johnson and Johnson (U.S.)
- Alcon (Switzerland)
- Microsurgical technology (U.S.)
- New World Medical (U.S.)
- Santen Pharmaceutical (Japan)
- Nova Eye Medical Limited (Australia)
- Belkin Vision (U.S.)
- Sight Scientific (U.S.)
SKU-